Comparison of two different treatment regimens' efficacy in neovascular age-related macular degeneration in Turkish population-based on real life data-Bosphorus RWE Study Group.

Autor:	Erden B; Ophthalmology Clinic, Okmeydanı Training and Research Hospital, Istanbul 34384, Turkey., Bölükbaşı S; Ophthalmology Clinic, Okmeydanı Training and Research Hospital, Istanbul 34384, Turkey., Özkaya A; Ophthalmology Clinic, Memorial Şişli Hospital, Istanbul 34384, Turkey., Karabaş L; Department of Ophthalmology, Kocaeli University Faculty of Medicine, Kocaeli 41380, Turkey., Alagöz C; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Alkın Z; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Artunay Ö; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Bayramoğlu SE; Ophthalmology Clinic, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul 34303, Turkey., Demir G; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Demir M; Ophthalmology Clinic, Şişli Etfal Training and Research Hospital, Istanbul 34360, Turkey., Demircan A; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Erdoğan G; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Erdoğan M; Ophthalmology Clinic, Şişli Etfal Training and Research Hospital, Istanbul 34360, Turkey., Eriş E; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Kaldırım H; Ophthalmology Clinic, Bağcılar Training and Research Hospital, Istanbul 34200, Turkey., Onur İU; Ophthalmology Clinic, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Turkey., Osmanbaşoğlu ÖA; Ophthalmology Clinic, Istanbul Training and Research Hospital, Istanbul 34098, Turkey., Özdoğan Erkul S; Ophthalmology Clinic, Istanbul Training and Research Hospital, Istanbul 34098, Turkey., Öztürk M; Ophthalmology Clinic, Haseki Training and Research Hospital, Istanbul 34096, Turkey., Perente İ; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Sarıcı K; Ophthalmology Clinic, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul 34303, Turkey., Sayın N; Ophthalmology Clinic, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul 34303, Turkey., Yaşa D; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Yılmaz İ; Ophthalmology Clinic, Beyoğlu Eye Training and Research Hospital, Istanbul 34421, Turkey., Yılmazabdurrahmanoğlu Z; Ophthalmology Clinic, Bağcılar Training and Research Hospital, Istanbul 34200, Turkey.
Jazyk:	angličtina
Zdroj:	International journal of ophthalmology [Int J Ophthalmol] 2020 Jan 18; Vol. 13 (1), pp. 104-111. Date of Electronic Publication: 2020 Jan 18 (Print Publication: 2020).
DOI:	10.18240/ijo.2020.01.15
Abstrakt:	Aim: To compare two different anti-vascular endothelial growth factor (anti-VEGF) treatment regimens'-a priori pro re nata (PRN) and PRN regimen following the loading phase-anatomical and functional results in neovascular age-related macular degeneration (nAMD) patients. Methods: Totally 544 nAMD patients followed and treated with aflibercept ( n =135) and ranibizumab ( n =409) at 9 different centers between 2013 and 2015 were enrolled into this retrospective multicenter study. Patients with initial best corrected visual acuity (BCVA) interval of 1.3-0.3 (logMAR) and a minimum follow-up of 12mo were included. Patients under two different regimens-a priori pro re nata (1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen (3+PRN)-were compared in BCVA at 3 th , 6 th and 12 th months, and in central macular thickness (CMT) at 6 th and 12 th months. The total study group, intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) groups were evaluated separately. Results: The mean CMT decreased in the 1+PRN ( n =101) regimen from 407 to 358 and 340 µm and in the 3+PRN ( n =443) group from 398 to 318 and finally to 310 µm at months 6 and 12, respectively. Anatomically, the CMT reduction at 6 th month (48.5 vs 76.4; P <0.05) was statistically significant in favor of 3+PRN group. BCVA changed in 1+PRN group from 0.77 to 0.78, 0.75 and 0.75; in 3+PRN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PRN group at 3 th month (-0.01 vs 0.12; P <0.001). In IVR group, CMT reduction was in greater in 3+PRN at 6 th (44 vs 72) and 12 th month (61 vs 84), but statistically insignificant. The 3+PRN group revealed statistically better visual results at 3 th month (-0.02 vs 0.11, P <0.05). In IVA group, although statistically insignificant, CMT reduction (61 vs 89, 6 th month; 85 vs 97, 12 th month) and visual gain (0.02 vs 0.16; 0.02 vs 0.14; 0.05 vs 0.11) was found in favor of 3+PRN group at all visits. Conclusion: The loading dose of anti-VEGF treatments in nAMD leads to significantly better anatomical and functional results, regardless of the agent, specially in early follow-up interval. (International Journal of Ophthalmology Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu